Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles - PubMed (original) (raw)
Review
Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles
Antonio Rossi et al. Expert Rev Anticancer Ther. 2016 Jun.
Free article
Abstract
Platinum-based chemotherapy remains the standard-of-care for most patients affected by advanced non-small cell lung cancer (NSCLC). The platinum compounds currently used in NSCLC are cisplatin and carboplatin. The availability of new generation drugs has led to the adoption of schedules with lower doses of platinum compounds leading to increased tolerability. Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. Recent evidence emphasized that the optimal number of first-line platinum cycles should be four for any NSCLC histology. New platinum compounds and the use of functional genomics to deliver platinum drugs as personalised medicine, are being investigated. Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients.
Keywords: Carboplatin; NSCLC; chemotherapy; cisplatin; first-line; metastatic; non-small-cell lung cancer; treatment.
Similar articles
- Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
Ramsden K, Laskin J, Ho C. Ramsden K, et al. Clin Oncol (R Coll Radiol). 2015 Jul;27(7):394-400. doi: 10.1016/j.clon.2015.03.001. Epub 2015 Mar 19. Clin Oncol (R Coll Radiol). 2015. PMID: 25800720 - Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ, Fernandes AL, Pereira JR, Curtis JR, Santoro IL. Costa GJ, et al. Lung Cancer. 2006 Aug;53(2):171-6. doi: 10.1016/j.lungcan.2006.04.006. Epub 2006 Jun 6. Lung Cancer. 2006. PMID: 16757059 - Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M. Kim YH, et al. Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6. doi: 10.1007/s00280-012-1910-2. Epub 2012 Jun 30. Cancer Chemother Pharmacol. 2012. PMID: 22752216 Clinical Trial. - [Treatment of the unresectable non small cell lung carcinoma].
Spásová I. Spásová I. Cas Lek Cesk. 2005;144(9):602-12; discussion 612-3. Cas Lek Cesk. 2005. PMID: 16193938 Review. Czech.
Cited by
- DCBLD2 Mediates Epithelial-Mesenchymal Transition-Induced Metastasis by Cisplatin in Lung Adenocarcinoma.
Chen X, Lv Y, Xu K, Wang X, Zhao Y, Li J, Qin X, Shi Y, Wang L, Chang A, Huang C, Xiang R. Chen X, et al. Cancers (Basel). 2021 Mar 19;13(6):1403. doi: 10.3390/cancers13061403. Cancers (Basel). 2021. PMID: 33808696 Free PMC article. - MnTnHex-2-PyP5+ Displays Anticancer Properties and Enhances Cisplatin Effects in Non-Small Cell Lung Cancer Cells.
Soares RB, Manguinhas R, Costa JG, Saraiva N, Gil N, Rosell R, Camões SP, Batinic-Haberle I, Spasojevic I, Castro M, Miranda JP, Amaro F, Pinto J, Fernandes AS, Guedes de Pinho P, Oliveira NG. Soares RB, et al. Antioxidants (Basel). 2022 Nov 7;11(11):2198. doi: 10.3390/antiox11112198. Antioxidants (Basel). 2022. PMID: 36358570 Free PMC article. - Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review.
Yang D, Dai R, Zhang Q, Fang P. Yang D, et al. Saudi J Biol Sci. 2018 Jul;25(5):888-894. doi: 10.1016/j.sjbs.2017.12.011. Epub 2017 Dec 27. Saudi J Biol Sci. 2018. PMID: 30108437 Free PMC article. - Analysis of real-world data to investigate evolving treatment sequencing patterns in advanced non-small cell lung cancers and their impact on survival.
Liu Z, Lee K, Cohn D, Zhang M, Ai L, Li M, Zhang X, Jun T, Higashi MK, Pan Q, Oh W, Stolovitzky G, Schadt E, Wang X, Li SD. Liu Z, et al. J Thorac Dis. 2023 May 30;15(5):2438-2449. doi: 10.21037/jtd-22-1481. Epub 2023 Apr 6. J Thorac Dis. 2023. PMID: 37324065 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical